08:05 AM EST, 11/11/2025 (MT Newswires) -- Palvella Therapeutics ( PVLA ) reported a Q3 loss Tuesday of $1.03 per diluted share, narrowing from a loss of $3.94 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.82.

The company reported no revenue for the quarter ended Sept. 30, as expected.

Cash and cash equivalents amounted to $63.6 million as of Sept. 30, which the company said would be sufficient to fund operations into H2 2027.

Shares of the company were up 3.2% in recent premarket activity.